Microsomal triglyceride transfer protein inhibitor
申请人:Pfizer Inc
公开号:US20040132745A1
公开(公告)日:2004-07-08
The present invention provides inhibitors of microsomal triglyceride transfer protein (MTP) and/or apolipoprotein B (Apo B) secretion having Formula (I) which are useful for the treatment of obesity and related diseases, as well as prevention and treatment of atherosclerosis and its clinical sequelae, for lowering serum lipids, and in the prevention and treatment of related diseases. The invention further relates to pharmaceutical compositions comprising the compounds of the present invention and to methods of treating obesity, atherosclerosis, and related diseases and/or conditions with the compounds of the present invention, either alone or in combination with other medicaments, including lipid-lowering agents.
1
[EN] SUBSTITUTED QUINOLINE COMPOUNDS<br/>[FR] COMPOSES DE QUINOLINE SUBSTITUES
申请人:PFIZER PROD INC
公开号:WO2005080373A1
公开(公告)日:2005-09-01
This invention relates to MTP/Apo-B secretion inhibitors of Formula (I) wherein R1-R7, X1, m and n are as defined in the specification, as well as pharmaceutical compositions comprising the compounds, and methods of use of the compounds and compositions. The compounds of the invention are useful in treating obesity and associated diseases, conditions or disorders.
This invention relates to MTP/Apo-B secretion inhibitors of Formula (I)
wherein R
1
-R
7
, X
1
, m and n are as defined in the specification, as well as pharmaceutical compositions comprising the compounds, and methods of use of the compounds and compositions. The compounds of the invention are useful in treating obesity and associated diseases, conditions or disorders.
COMPOUNDS AND COMPOSITIONS USEFUL AS CATHEPSIN S INHIBITORS
申请人:Hart Terance William
公开号:US20090048230A1
公开(公告)日:2009-02-19
The present invention relates to the use of a 2-cyanopyrimidine compound of the formula
wherein
R
1
, R
2
, R
3
and X are as defined in the specification and in the claims, in free form or in salt form, and, where possible, in tautomeric form, as an inhibitor of the activity of cathepsin S.
Compounds and compositions useful as cathepsin S inhibitors
申请人:Novartis AG
公开号:US07704996B2
公开(公告)日:2010-04-27
The present invention relates to the use of a 2-cyanopyrimidine compound of the formula
wherein
R1, R2, R3 and X are as defined in the specification and in the claims, in free form or in salt form, and, where possible, in tautomeric form, as an inhibitor of the activity of cathepsin S.